QC
CORT icon

Quent Capital’s Corcept Therapeutics CORT Stock Holding History

Quent Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.4K Buy
200
+117
+141% +$7.07K ﹤0.01% 1102
2026
Q1 		$3.35K Buy
83
+63
+315% +$2.36K ﹤0.01% 1332
2025
Q4 		$696 Sell
20
-24
-55% -$1.89K ﹤0.01% 1496
2025
Q3 		$3.66K Buy
+44
New +$3.18K ﹤0.01% 1194

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quent Capital's CORT Position: Q2 2026 in Review

Quent Capital increased its Corcept Therapeutics (CORT) stake by 141% in Q2 2026, buying an estimated $7.07K and bringing the position to 200 shares worth $17.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1102.

Quent Capital first reported a position in CORT in Q3 2025 and has held it in 4 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Quent Capital held 200 shares of Corcept Therapeutics worth $17.4K as of Q2 2026.
  • Quent Capital bought 117 Corcept Therapeutics shares in Q2 2026, an estimated $7.07K.
  • Corcept Therapeutics made up ﹤0.01% of Quent Capital's portfolio in Q2 2026, its #1102 holding.
  • Quent Capital first reported a position in Corcept Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Quent Capital's 13F filing for Q2 2026, filed 7 Aug 2026.